🚨 With more emerging 1L options than ever for HER2+ MBC, how should we choose?
Check out our new @JAMAOnc publication: Evolving First-Line Treatment Strategies in ERBB2-Positive Metastatic Breast Cancer
🔓jamanetwork.com/journals/jamao…
@DrLisaCarey @YAbdouMD
#BreastCancer #HER2
Check out our new @JAMAOnc publication: Evolving First-Line Treatment Strategies in ERBB2-Positive Metastatic Breast Cancer
🔓jamanetwork.com/journals/jamao…
@DrLisaCarey @YAbdouMD
#BreastCancer #HER2